IV Infusion to Oral Dosing: Conversion Methods

The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.

Pharmacokinetics of the Transition

Discontinuing intravenous infusions results in a decline in serum drug concentrations, following first-order elimination kinetics. Oral dosing must be carefully calculated to counteract this drop and establish a new steady state. Extended-release formulations play a key role by allowing for steady drug release over an extended period, mimicking the constant drug levels achieved with intravenous infusions.

Calculating Oral Dosage Regimens

Two primary methods are used to transition from intravenous to oral regimens. The first method ensures that the steady-state plasma concentration achieved with intravenous infusion is matched with oral dosing. This calculation incorporates critical parameters such as the drug’s salt factor, bioavailability, and dosing rate. Consider transitioning a patient from an intravenous theophylline regimen to oral therapy, considering the oral bioavailability of theophylline is 100% (F = 1) and a 28.9 mg/h dosing rate. Using the formula for oral dosage, an oral dose of approximately 700 mg daily is required. This dose is often divided into two 350 mg doses of controlled-release theophylline administered every 12 hours.

The second method directly equates the intravenous infusion rate to the desired oral dosing rate. While simpler to apply, this approach does not account for differences in bioavailability or the effects of dosing schedules, which may lead to inaccuracies in maintaining therapeutic drug levels.

By employing precise pharmacokinetic calculations and considering drug-specific properties, healthcare providers can ensure effective and safe transitions from intravenous to oral therapy, optimizing patient treatment outcomes.